Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $15.08 which represents a decrease of $-0.01 or -0.07% from the prior close of $15.09. The stock opened at $15.46 and touched a low of $14.9 ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.98 which represents a decrease of $-0.46 or -2.98% from the prior close of $15.44. The stock opened at $16.11 and touched a low of ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

On May 6, 2021, plaintiffs sued defendants for patent infringement in the United States District Court for the District of Delaware. The parties ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and competition warrant a Sell rating.

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

Stifel Nicolaus analyst Daniel Arias has maintained their bullish stance on TXG stock, giving a Buy rating yesterday.Stay Ahead of the ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...